The Current Ratio as of November 2024 (TTM) for MiNK Therapeutics, Inc. (INKT) is 0.93

According to MiNK Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 0.93. This represents a change of 54.85% compared to the average of 0.60 of the last 4 quarters.

MiNK Therapeutics, Inc. (INKT) Historical Current Ratio (quarterly & annually)

How has INKT Current Ratio performed in the past?

The mean historical Current Ratio of MiNK Therapeutics, Inc. over the last ten years is 0.95. The current 0.93 Current Ratio has changed 9.74% with respect to the historical average. Over the past ten years (40 quarters), INKT's Current Ratio was at its highest in in the December 2021 quarter at 2.41. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

MiNK Therapeutics, Inc. (INKT) Current Ratio by Quarter and Year

Discovering the peaks and valleys of MiNK Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

MiNK Therapeutics, Inc. (INKT) Average Current Ratio

How has INKT Current Ratio performed in the past?

The current Current Ratio of MiNK Therapeutics, Inc. (INKT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

MiNK Therapeutics, Inc. (INKT) Current Ratio vs. Peers

How is INKT’s Current Ratio compared to its peers?

MiNK Therapeutics, Inc.’s Current Ratio is less than Affimed N.V. (2.71), less than ImmunoGen, Inc. (5.47), less than Adaptimmune Therapeutics plc (3.09), less than Sangamo Therapeutics, Inc. (1.03), less than Day One Biopharmaceuticals, Inc. (14.62), less than Acumen Pharmaceuticals, Inc. (17.37), less than X4 Pharmaceuticals, Inc. (6.07), less than Inozyme Pharma, Inc. (9.84), less than VectivBio Holding AG (9.14), less than Terns Pharmaceuticals, Inc. (21.02), less than HOOKIPA Pharma Inc. (3.86), greater than Kineta, Inc. (0.14), less than Candel Therapeutics, Inc. (1.62), less than Forte Biosciences, Inc. (2.82), less than AlloVir, Inc. (55.08), less than Monte Rosa Therapeutics, Inc. (6.56), less than Design Therapeutics, Inc. (41.42), less than Werewolf Therapeutics, Inc. (12.13), less than Ikena Oncology, Inc. (18.22), less than Stoke Therapeutics, Inc. (6.67),

Build a custom stock screener for MiNK Therapeutics, Inc. (INKT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MiNK Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

MiNK Therapeutics, Inc. (INKT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like MiNK Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.